Trial Condition(s):

Stroke

Xarelto on prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation in China: A non-interventional study (XASSURE)

Bayer Identifier:

16819

ClinicalTrials.gov Identifier:

NCT02784717

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This non-interventional field study will investigate rivaroxaban under clinical practice conditions for stroke prevention and for prevention of non-CNS systemic embolism in patients with non-valvular atrial fibrillation in China.

Inclusion Criteria
- Female and male patients ≥ 18 years of age diagnosed with non-valvular atrial fibrillation
        - Patients for whom the decision to initiate treatment with rivaroxaban to prevent stroke or non-CNS systemic embolism was made as per investigator’s routine treatment practice
Exclusion Criteria
-NA

Trial Summary

Enrollment Goal
3055
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

HangZhou, China

Status
Completed
 

Trial Design